Medical Oncologist, Breast Cancer Group - San Raffaele Scientific Institute
Milan, Lombardy
Joined March 2023
- Tweets86
- Following37
- Followers190
- Likes75
Pinned Tweet
📢1/8 A subset of ER+/HER2- #breastcancer may benefit from #immunotherapy, but which tumors are these?🤔
Our latest study just out on @BrJCancer @SpringerNature sheds light on this highly relevant topic
Read more:📌rdcu.be/dqys9
@BianchiniGP @mauricallari
Our review on the challenges and evidence gaps in treating premenopausal women with HR+/HER2− early #BreastCancer is now officially published in @Annals_Oncology @myESMO
📌doi.org/10.1016/j.annonc.202…
Many thanks again to all co-authors for this collaborative effort!
🧵 HR+/HER2− early breast cancer in young women: evidence is growing, but many treatment decisions remain uncertain.
In our new @Annals_Oncology review, we provide a pragmatic framework to navigate these grey areas—highlighting what we know and what we still don’t know.
A few key questions 👇
kwnsfk27.r.eu-west-1.awstrac…
🧵 HR+/HER2− early breast cancer in young women: evidence is growing, but many treatment decisions remain uncertain.
In our new @Annals_Oncology review, we provide a pragmatic framework to navigate these grey areas—highlighting what we know and what we still don’t know.
A few key questions 👇
kwnsfk27.r.eu-west-1.awstrac…
📣Another step forward for #precision_immunotherapy in breast cancer!
🚀Just out in @Nature_NPJ Breast Cancer our exploratory analysis of the NeoTRIP trial showing the role of tumor-specific MHC-II as a predictor of immunotherapy benefit in #TNBC.
📌rdcu.be/eIKAH
🚨Just out in @CCR_AACR our analysis on the recurrence timing after neoadjuvant chemo-immunotherapy in early-stage TNBC
We analyzed 5 major trials
👉 Early relapse: up to 83% of all recurrences🤯
1/ 🧵 Why this matters 👇
🔗 Full article: doi.org/10.1158/1078-0432.CC…
Just out on @JAMANetworkOpen our study on the fate of immunotherapy trials in breast cancer, led by @mariani_m97
Take a look at the terrific job and excellent tweetorial he did 👏
@BianchiniGP @SanRaffaeleMI @OncoAlert
Excited to share our latest publication on @JAMANetworkOpen : "Completion rate and positive results reporting among immunotherapy trials in breast cancer, 2004-2023.”
#BreastCancerResearch @OncoAlert @SanRaffaeleMI
👇Check out some key insights below
Just out in Cancer Treatment Reviews our manuscript on how to navigate the practical challenges in #immunotherapy for #mTNBC that cannot be addressed by clinical trials data
🌟What a pleasure joining this stellar team!🌟
@BianchiniGP @curijoey @JavierCortesMD @lajos_pusztai
1/3
📢 The largest study (N=1,133) on the real‐world use of multigene assays in early #breastcancer conducted after the availability of data from TAILORx, RxPONDER, and MINDACT trials is just out on Breast Cancer Res Treat
rdcu.be/dwSa7
@BianchiniGP
Not all ER+/HER2- BC may benefit from immunoTx.
🌟Biomarker analyses of KN-756 and CheckMate7FL studies at @SABCS provide key contribution to #PrecisionImmunology in BC and corroborate our data:
Tumors with ⬇️ER benefit the most.
Read more 👉rdcu.be/dqys9
@BianchiniGP
A subset of ER+/HER2- #breastcancer may benefit from #immunotherapy, but which? Grade 3 alone (as in KN-756 & CM-7FL) is not such a precise selector.
Our study proposes a different & more precise way to identify these tumors.
📌 Read more: rdcu.be/dqys9
@BianchiniGP
Excellent presentation by @BianchiniGP at @myESMO 2023 congress on precision immunology in #breastcancer
The integration of several biomarkers into a single “cancer immunogram” is the key.
If interested, take a look at our review in @TheBreastOnline
thebreastonline.com/action/s…
Thread by @BianchiniGP on Thread Reader App threadreaderapp.com/thread/1…
📢(1/5) Just published in @Nature_NPJ Breast Cancer our study assessing how Oncotype DX results impact physicians' confidence and concordance in adjuvant chemotherapy recommendations for early breast cancer patients.
Read more: 📌rdcu.be/dd3nv
👇👇👇
